Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Caribou Biosciences (CRBU) over the last 6 years, with Dec 2024 value amounting to $16.3 million.

  • Caribou Biosciences' Cash & Equivalents fell 65.14% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 65.14%. This contributed to the annual value of $16.3 million for FY2024, which is 68.15% down from last year.
  • Per Caribou Biosciences' latest filing, its Cash & Equivalents stood at $16.3 million for FY2024, which was down 68.15% from $51.2 million recorded in FY2023.
  • Caribou Biosciences' Cash & Equivalents' 5-year high stood at $240.4 million during FY2021, with a 5-year trough of $16.0 million in FY2020.
  • In the last 3 years, Caribou Biosciences' Cash & Equivalents had a median value of $51.2 million in 2023 and averaged $41.9 million.
  • In the last 5 years, Caribou Biosciences' Cash & Equivalents surged by 1,407.05% in 2021 and then crashed by 75.73% in 2022.
  • Caribou Biosciences' Cash & Equivalents (Yearly) stood at $16.0 million in 2020, then spiked by 1,407.05% to $240.4 million in 2021, then tumbled by 75.73% to $58.3 million in 2022, then fell by 12.30% to $51.2 million in 2023, then crashed by 68.15% to $16.3 million in 2024.